Advanced Solid Tumors Clinical Trials in Salt Lake City, Utah

4 studies are recruiting for advanced solid tumors in Salt Lake City, Utah right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

    The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include …

    Stage
    Phase 2
    Ages
    12 and older
    Site
    Intermountain Healthcare, Salt Lake City, Utah
    Locations
    181 in total
    Run by
    American Society of Clinical Oncology

    See if you can join NCT02693535 on ClinicalTrials.gov

  2. Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

    Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Huntsman Cancer Institute, Salt Lake City, Utah
    Locations
    21 in total
    Run by
    Revolution Medicines, Inc.

    See if you can join NCT05379985 on ClinicalTrials.gov

  3. JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

    This study is to evaluate the safety and tolerability of pan-KRAS inhibitor JAB-23E73 in adult participants with advanced solid tumors

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Huntsman Cancer Institute, Salt Lake City, Utah
    Locations
    4 in total
    Run by
    Jacobio Pharmaceuticals Co., Ltd.

    See if you can join NCT06973564 on ClinicalTrials.gov

  4. Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS

    This study will evaluate the safety, tolerability, drug levels, pharmacodynamic effects, and clinical activity of YL 17231 in patients with advanced solid tumors harboring mutations in KRAS, HRAS, or NRAS.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Huntsman Cancer Institute and Hospital, University of Utah, Salt Lake City, Utah
    Locations
    3 in total
    Run by
    Shanghai YingLi Pharmaceutical Co. Ltd.

    See if you can join NCT06096974 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.